Literature DB >> 27281838

Diagnosis and Management of Ovarian Cancer.

Chyke A Doubeni1, Anna R Doubeni1, Allison E Myers1.   

Abstract

Ovarian cancer is the most lethal gynecologic cancer. Less than one-half of patients survive for more than five years after diagnosis. Ovarian cancer affects women of all ages but is most commonly diagnosed after menopause. More than 75% of affected women are diagnosed at an advanced stage because early-stage disease is usually asymptomatic and symptoms of late-stage disease are nonspecific. The strongest risk factors are advancing age and family history of ovarian and breast cancer. Women who have symptoms concerning for ovarian cancer should undergo a physical examination, transvaginal ultrasonography, and measurement of biomarkers such as cancer antigen 125. If results are suspicious for ovarian cancer, the patient should be referred to a gynecologic oncologist. Despite the low rate of early diagnosis, guidelines recommend against routine screening for ovarian cancer in average-risk women because screening, including routine pelvic examinations, is ineffective and associated with harm. However, a recent trial found a potential benefit of annual screening using an algorithm based on serial cancer antigen 125 measurements followed by transvaginal ultrasonography for women at increased risk, as determined by the algorithm. Women with an increased-risk family history should be referred for genetic counseling and, if genetic mutations (e.g., BRCA mutations) are identified, bilateral salpingo-oophorectomy can be considered for risk reduction. In both average- and high-risk women, long-term hormonal contraceptive use reduces risk by about 50%. The treatment of ovarian cancer usually involves surgery, with or without intraperitoneal and intravenous chemotherapy. Primary care physicians have important roles in posttreatment surveillance and end-of-life care.

Entities:  

Mesh:

Year:  2016        PMID: 27281838

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  83 in total

1.  Amplification of lncRNA PVT1 promotes ovarian cancer proliferation by binding to miR-140.

Authors:  Yuqin Ding; Qianjin Fang; Yan Li; Yanni Wang
Journal:  Mamm Genome       Date:  2019-06-20       Impact factor: 2.957

Review 2.  Multimodality imaging and genomics of granulosa cell tumors.

Authors:  Sherif Elsherif; Matthew Bourne; Erik Soule; Chandana Lall; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-03

3.  Migration dynamics of ovarian epithelial cells on micro-fabricated image-based models of normal and malignant stroma.

Authors:  Samuel Alkmin; Rebecca Brodziski; Haleigh Simon; Daniel Hinton; Randall H Goldsmith; Manish Patankar; Paul J Campagnola
Journal:  Acta Biomater       Date:  2019-09-27       Impact factor: 8.947

4.  Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.

Authors:  Bahareh Kashani; Zahra Zandi; Mohammad Reza Karimzadeh; Davood Bashash; Ali Nasrollahzadeh; Seyed H Ghaffari
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

5.  Long non-coding RNA LINC00504 regulates the Warburg effect in ovarian cancer through inhibition of miR-1244.

Authors:  Ya Liu; Xiaocui He; Yuli Chen; Dan Cao
Journal:  Mol Cell Biochem       Date:  2019-11-05       Impact factor: 3.396

6.  Evaluation of Lactate Dehydrogenase Tumor Marker in Children with Gonadal Germ Cell Tumor, Epithelial Tumor, Sex Stromal Tumor, Paragonadal Tumor, and Cyst.

Authors:  Usiwoma-Okeroghene Ataikiru; Emil-Radu Iacob; Calin-Marius Popoiu; Eugen-Sorin Boia
Journal:  Indian J Pediatr       Date:  2021-07-30       Impact factor: 1.967

Review 7.  Current update on the molecular genetics and management of hereditary ovarian cancers: a primer for radiologists.

Authors:  Malak Itani; Neeraj Lalwani; Dhakshinamoorthy Ganeshan; Maria Zulfiqar; Cary Siegel
Journal:  Abdom Radiol (NY)       Date:  2021-04-13

Review 8.  'Lnc'-ing Wnt in female reproductive cancers: therapeutic potential of long non-coding RNAs in Wnt signalling.

Authors:  Mei S Ong; Wanpei Cai; Yi Yuan; Hin C Leong; Tuan Z Tan; Asad Mohammad; Ming L You; Frank Arfuso; Boon C Goh; Sudha Warrier; Gautam Sethi; Nicholas S Tolwinski; Peter E Lobie; Celestial T Yap; Shing C Hooi; Ruby Y Huang; Alan P Kumar
Journal:  Br J Pharmacol       Date:  2017-08-23       Impact factor: 8.739

9.  A BRCA1 Splice Site Variant Responsible for Familial Ovarian Cancer in a Han-Chinese Family.

Authors:  Peng-Zhi Hu; Xiang-Yu Chen; Wei Xiong; Zhi-Jian Yang; Xiao-Rong Li; Wen-Zhi Deng; Li-Na Gong; Hao Deng; La-Mei Yuan
Journal:  Curr Med Sci       Date:  2022-03-15

10.  Bone marrow stromal cells-derived microRNA-181-containing extracellular vesicles inhibit ovarian cancer cell chemoresistance by downregulating MEST via the Wnt/β-catenin signaling pathway.

Authors:  Zhengyi Ruan; Lili Lu; Li Zhang; Min Dong
Journal:  Cancer Gene Ther       Date:  2020-07-07       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.